Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 2627 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2012  |  Volume : 16  |  Issue : 8  |  Page : 428-429

Physician perceptions and practices in management of diabetes in India: Results from the IMPROVE Control program

1 Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi, India
2 Endocrinologist, Indraprastha Apollo Hospitals, New Delhi, India
3 Consultant Endocrinologist at Joshi Clinic, Lilavati & Bhatia Hospitals, Mumbai, India
4 Department of Medicine, Vivekananda Institute of Medical Sciences, Kolkata, India
5 Diabetes Care and Research Centre, Patna, India
6 Bharti Hospital & B.R.I.D.E., Karnal, India
7 Novo Nordisk India Private Limited, Bangalore, India

Correspondence Address:
A G Unnikrishnan
Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi
Login to access the Email id

Source of Support: Unrestricted educational grant from novonordisk India Limited, Conflict of Interest: None

DOI: 10.4103/2230-8210.104118

Rights and Permissions

Introduction: The impact of IMPROVE Control Training program was evaluated by a non-interventional study and validated by a physician perception questionnaire. From a survey on 1086 physicians providing diabetes care in India, we report their practices and perceptions about diabetes care and insulin therapy. Materials and Methods: The responses were collected using a questionnaire validated by the IMPROVE Control Steering Committee. Results: Majority [558 (51.4%)] of the physicians accepted the ADA defined HbA1c target of <7% as the standard for good glycemic control in their practice. However, 541 (49.8%) of the physicians agreed that only 20-40% of their patients were able to achieve this target. For patients who do not achieve the glycemic control with oral anti-diabetic drugs (OADs) within 6 months of initiation of therapy, initiation of an optimal insulin regimen was the preferred choice for 492 (45.3%) of the participating physicians. Premixed insulin was preferred for initiating insulin therapy in patients with type 2 diabetes, by 676 (62.2%) of the participants [as compared to basal by 375 (34.5%) participants]. Once daily premixed insulin, intensified to twice daily was preferred as most optimal insulin regimen for initiation and subsequent intensification of insulin therapy [487 (44.8%) participants]. Most of the participants preferred adopting a multi-targeted approach for treating diabetes, hypertension, and dyslipidemia. Conclusions: Physicians prefer treatment goals similar to those recommended in the current guidelines of the American Diabetes Association for managing their patients with diabetes. Premixed insulin is preferred for initiation and intensification of insulin therapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded231    
    Comments [Add]    

Recommend this journal